• New Protocol

    A new law taking effect this September designed to protect New Jersey college students against meningitis outbreaks were signed by legislators. The legislation, revises the requirement for residential students in four-year institutions of higher education to receive immunization against meningococcal disease. Such immunization protocol will now follow more stringent federal guidelines laid out by the Advisory Committee on […]

    Continue reading
  • Two Shots

    It takes two different types of vaccines to help protect against the five vaccine-preventable types of meningococcal bacteria — A, B, C, W and Y. Meningitis is a life-threatening bacterial infection that can affect the lining of the brain and spinal cord, or it can cause an infection in the bloodstream — or both. Meningitis […]

    Continue reading
  • Complete Coverage Vaccination

    Sara Stelzer, a freshman from San Diego State University, on a Saturday called her parents to complain of a bad headache soon paired with exhaustion and nausea. By Tuesday morning, a friend of Sara’s informed Greg and his wife Laurie via text message that Sara was in the emergency room. Though Sara’s doctors, after determining she […]

    Continue reading
  • College Meningitis Outbreaks

    Outbreaks of type B meningococcal disease were reported on 20 college campuses from March 2013 to November 2017 according to the National Meningitis Association.

    Continue reading
  • Vaccinate Please!

    Purdue University and Indiana University announced starting in the fall semester, incoming students will be required to receive the meningitis B vaccine.

    Continue reading
  • Vaccine Approved

    Health Canada approved in October 2017 TRUMENBA, meningococcal group B vaccine.

    Continue reading
  • Same Serogroup

    The same serogroup as the strain found during the recent Meningitis outbreak at University of Massachusetts & Smith College was confirmed by laboratory results.

    Continue reading
  • Approval Granted

    The European Commission (EC) has approved the Meningococcal Group B Vaccine TRUMENBA (by Pfizer, Inc) for the prevention of invasive meningococcal disease caused by Neisseria Meningitides (MenB) for individuals 10 years of age and older.

    Continue reading
  • Don’t Forget B

    Meningitis outbreaks have become a reality for many colleges across the United States.

    Continue reading